Search

Harney District Hospital Community Assistance

Harney District Hospital Community Assistance

May 21, 2024

Savanna Cate, (left) program outreach coordinator for the Harney District Hospital Community Assistance for Neighbors with Cancer Program, shares information with patient Debbie Pike. The Burns, Oregon, program received a new grant to conduct a needs assessment of cancer patients in Harney County to identify cancer-related needs and barriers to care. (Photo courtesy Harney District Hospital Community Assistance for Neighbors with Cancer Program)

Thomas Deloughery, M.D., M.A.C.P., FAWM

Thomas Deloughery, M.D., M.A.C.P., FAWM

May 21, 2024

Thomas Deloughery, M.D., professor of Hematology/Oncology in the OHSU School of Medicine, and a practitioner at the OHSU Knight Cancer Institute. (OHSU/Kristyna Wentz-Graff)

Center for Experimental Therapeutics translates lab discoveries to treatments

Center for Experimental Therapeutics translates lab discoveries to treatments

May 21, 2024

The Center for Experimental Therapeutics at the OHSU Knight Cancer Institute provides expertise in pharmacology, toxicology and chemistry for new drug development, along with access to chemical compounds, high-throughput screening services and a wide range of model test systems. (OHSU/Christine Torres Hicks)

Sanjay Malhotra and Shivaani Kummar

Sanjay Malhotra and Shivaani Kummar

May 21, 2024

Shivaani Kummar, M.D., head of the division of hematology and medical oncology in the OHSU School of Medicine, and Sanjay Malhotra, Ph.D., right, are co-directors of the Knight Cancer Institute’s Center for Experimental Therapeutics. Malhotra is a professor in the departments of cell, developmental and cancer biology and oncological sciences in the OHSU School of Medicine. (OHSU/Christine Torres Hicks)

Sanjay Malhotra lab at the OHSU Knight Cancer Institute

Sanjay Malhotra lab at the OHSU Knight Cancer Institute

May 21, 2024

Dhanir Tailor, Ph.D., left, Sanjay Malhotra, Ph.D., and Arpit Dheeraj, Ph.D., are among the developers of the first drug that targets YB-1, an important signaling point in many different cancers. The drug has shown powerful anti-tumor activity in animal models of several different tumor types. (OHSU/Christine Torres Hicks)

See More Stories